Skip to content

Nurix

Inside The Science
Advancing Our Pipeline
- Pipeline
- Clinical Trials
Learn About Us
Work at Nurix
- Our Culture
- Explore Jobs

Nurix

Inside The Science
Advancing Our Pipeline
- Pipeline
- Clinical Trials
Learn About Us
Work at Nurix
- Our Culture
- Explore Jobs

Kinase Impaired BTK Mutations Are Susceptible to Clinical Stage BTK and IKZF1/3 Degrader NX-2127

By AldenMC Production / January 30, 2024

Post navigation

Discovery and Preclinical Pharmacology of NX-2127, an Orally Bioavailable Degrader of Bruton’s Tyrosine Kinase with Immunomodulatory Activity for the Treatment of Patients with B Cell Malignancies

Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies

WHERE SCIENCE EXPANDS POSSIBILITIES

Inside The Science

DEL-AI Discovery Engine
Targeted Protein Degradation
Resource Library

Advancing Our Pipeline

Pipeline
Clinical Trials

Learn About Us

Our Story
Leadership
Partnering
Contact Us

Work at Nurix

Our Culture
Explore Jobs

For Investors

News & Events
Financial Information
Stock Information
Corporate Governance
FAQs
Investor Contact

For Patients

Resources

©2025 Nurix Therapeutics, Inc.

You are now leaving the nurixtx.com website. This link will take you to a website to which our Privacy Policy does not apply. You are solely responsible for your interactions with that website.

Cancel

Continue